DSCO

Discovery Labs Receives FDA Recommendations and Request for Clarification Regarding Recently-Submitted SURFAXIN® (lucinactant) Updated Product Specifications

[at noodls] – Discovery Labs Receives FDA Recommendations and Request for Clarification Regarding Recently-Submitted SURFAXIN® (lucinactant) Updated Product Specifications Warrington, PA – April 15, 2013 – Discovery … moreView todays social media effects on DSCOView the latest stocks trending across Twitter. Click to view dashboardSee who Discovery is hiring next, click here to view […]

Discovery Labs Announces Newly-Released SURFAXIN® (lucinactant) Publications

[at noodls] – Discovery Labs Announces Newly-Released SURFAXIN® (lucinactant) Publications Warrington, PA – March 29, 2013- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to … moreView todays social media effects on DSCOView the latest stocks trending across Twitter. Click to view dashboardSee who Discovery is hiring next, click here to view […]

Discovery Labs Reports Fourth Quarter 2012 Financial Results

[at noodls] – Warrington, PA – March 13, 2013 – Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today reports financial … moreView todays social media effects on DSCOView the latest stocks trending across Twitter. Click to view dashboardSee who Discovery is hiring next, click here to view […]

Discovery Labs to Report Fourth Quarter 2012 Results and Hold Conference Call on Wednesday, March 13, 2013

[at noodls] – Discovery Labs to Report Fourth Quarter 2012 Results and Hold Conference Call on Wednesday, March 13, 2013 Warrington, PA – March 6, 2013 – Discovery Laboratories, Inc. (Nasdaq: DSCO) will report fourth … moreView todays social media effects on DSCOView the latest stocks trending across Twitter. Click to view dashboardSee who Discovery is hiring next, click here […]

Discovery Labs Receives $30 Million Funding Commitment from Deerfield Management

[at noodls] – Warrington, PA – February 13, 2013 – Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that … moreView todays social media effects on DSCOView the latest stocks trending across Twitter. Click to view dashboardSee who Discovery is hiring next, click here to view […]

Discovery Labs Receives New US Patent for Pulmonary Surfactant Formulations

[at noodls] – Discovery Labs Receives New US Patent for Pulmonary Surfactant Formulations Warrington, PA – January 17, 2013 – Discovery Laboratories, Inc. (Nasdaq: DSCO) today announced it has received a patent issued … moreView todays social media effects on DSCOView the latest stocks trending across Twitter. Click to view dashboardSee who Discovery is hiring next, click here to view […]

Discovery Labs Initiates Launch of AFECTAIR®

[at noodls] – Discovery Labs Initiates Launch of AFECTAIR® First Phase of Launch Introduces New, Proprietary Technology to Select Neonatal and Pediatric Critical Care Centers Warrington, PA – January 03, 2013 – Discovery … moreView todays social media effects on DSCOView the latest stocks trending across Twitter. Click to view dashboardSee who Discovery is hiring next, click here to view […]

Discovery Labs Announces Changes to Board of Directors and Appoints a New Chief Executive Officer

[at noodls] – Discovery Labs Announces Changes to Board of Directors and Appoints a New Chief Executive Officer Warrington, PA – January 04, 2013 – Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology … moreView todays social media effects on DSCOView the latest stocks trending across Twitter. Click to view dashboardSee who Discovery is hiring next, click here to view […]

New Pharmacoeconomic Analysis Shows Lower Rate of Reintubation Observed With SURFAXIN® Treatment May Reduce Hospital Costs Associated with Bronchopulmonary Dysplasia

[at noodls] – New Pharmacoeconomic Analysis Shows Lower Rate of Reintubation Observed With SURFAXIN® Treatment May Reduce Hospital Costs Associated with Bronchopulmonary Dysplasia New Analysis Presented at 2012 Hot … moreView todays social media effects on DSCOView the latest stocks trending across Twitter. Click to view dashboardSee who Discovery is hiring next, click here to view […]

Discovery Labs Presents New SURFAXIN® and AFECTAIR Data at 2012 Hot Topics in Neonatology Annual Meeting

[at noodls] – Discovery Labs Presents New SURFAXIN® and AFECTAIR® Data at 2012 Hot Topics in Neonatology Annual Meeting Warrington, PA – November 28, 2012- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced … moreView todays social media effects on DSCOView the latest stocks trending across Twitter. Click to view dashboard […]